🎗️ Oncology

Ovarian Cancer

Often presents late with vague abdominal symptoms — early recognition saves lives.

Overview

Ovarian cancer is the leading cause of gynaecological cancer death. Most are high-grade serous carcinomas, often originating in the fallopian tube. Symptoms (bloating, early satiety, urinary urgency, pelvic pain) are non-specific and frequently attributed to IBS or menopause, delaying diagnosis.

Symptoms

  • • Persistent abdominal bloating
  • • Early satiety or loss of appetite
  • • Pelvic or abdominal pain
  • • Urinary urgency or frequency
  • • Change in bowel habit, fatigue, unexplained weight loss

Risk factors

  • • Age >50
  • • Family history of ovarian, breast, colorectal cancer
  • • BRCA mutation, Lynch syndrome
  • • Obesity, HRT (small increase)

Causes

  • • BRCA1/2 (~15%), Lynch syndrome, RAD51, BRIP1, PALB2
  • • Lifelong number of ovulations (nulliparity, early menarche, late menopause increase risk)
  • • Endometriosis (clear cell, endometrioid subtypes)

🚨 Red flags — seek urgent care

  • • New persistent bloating > 12 times/month in a woman over 50
  • • Ascites or palpable pelvic/abdominal mass
  • • Postmenopausal bleeding with bloating
  • • Bowel obstruction in a woman with vague abdominal symptoms

When to seek care

  • • Any new persistent (>3 weeks) bloating, pelvic pain or urinary symptoms in women over 50
  • • Family history meeting genetic referral criteria
  • • Sudden severe abdominal pain — exclude ovarian torsion

Diagnosis

  • • CA-125 and pelvic ultrasound as first-line in women >50 with symptoms
  • • Risk of Malignancy Index (RMI) or ROMA to triage
  • • CT chest/abdomen/pelvis for staging
  • • Histological confirmation: laparoscopic or image-guided biopsy
  • • BRCA and somatic tumour testing in all epithelial ovarian cancers

Treatment

  • • Primary cytoreductive surgery aiming for no macroscopic residual disease
  • • Carboplatin + paclitaxel chemotherapy (neoadjuvant or adjuvant)
  • • Maintenance PARP inhibitor (olaparib, niraparib) for BRCA-mutated or HRD-positive disease
  • • Bevacizumab maintenance in selected high-risk disease
  • • Hormonal therapy for low-grade serous; targeted/immunotherapy in clinical trials

Prevention

  • • Combined oral contraceptive reduces risk by ~50% with 5 years' use
  • • Bilateral salpingo-oophorectomy for BRCA carriers after childbearing
  • • Opportunistic salpingectomy at other pelvic surgery may reduce risk

Complications

  • • Bowel obstruction, ascites, pleural effusion
  • • VTE (high risk in advanced ovarian cancer)
  • • Chemotherapy: neuropathy, neutropenia, alopecia
  • • Recurrence — usually within 2 years for advanced disease

Prognosis

5-year survival ~93% stage I but ~13% stage IV; PARP inhibitor maintenance has substantially improved outcomes in BRCA-mutated and HRD-positive disease.

Education & self-care

Ovarian cancer's symptoms are vague but recognisable when persistent. Acting on them early — and engaging with genetic services when relevant — saves lives.

Frequently asked questions

Is bloating always serious?

Usually not — but persistent daily bloating in women over 50 deserves CA-125 and ultrasound.

Should I have BRCA testing?

Offered when family or personal history meets NICE criteria, or at any ovarian cancer diagnosis.

Does HRT cause ovarian cancer?

There is a small increased risk with long-term use — discuss benefits and risks individually.

Medically reviewed by Dr. Handel Emery, MD, FRCP (UK) · Last reviewed 2026-06-08